227. オスラー病 Osler disease Clinical trials / Disease details
臨床試験数 : 54 / 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04646356 (ClinicalTrials.gov) | October 20, 2020 | 20/10/2020 | Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed | Drug: Tacrolimus capsule (low-dose) | Unity Health Toronto | United States Department of Defense | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Canada |
| 2 | EUCTR2019-003585-40-NL (EUCTR) | 17/12/2019 | 30/09/2019 | Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patients | An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia - Tacrolimus for bleeding in HHT patients | Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by mucocutaneous telangiectasis. Telangiectasis predominantly observed in the nasal mucosa and gut, and are abnormal, thin walled blood vessel that can easily rupture leading to hemorrhage. MedDRA version: 20.0;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Tacrolimus (Advagraf) Product Name: Tacrolimus (Advagraf) Product Code: EMEA/H/C/000712 | St. Antonius Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Netherlands |